PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25869321-1	2015	LXR (encoded by NR1H2 and 3) and FXR (known as bile acid receptor) encoded by NR1H4 (nuclear receptor subfamily 1, group H and member 4) are nuclear receptors in humans and are important regulators of bile acid production, cholesterol, fatty acid and glucose homeostasis hence responsible for liver detoxification.	Fatty Acids	236-246	nuclear receptor subfamily 1 group H member 4	Homo sapiens	33-36	
26824277-2	2016	Results/methodology: In this study we optimized the fatty acid mimetic compound pirinixic acid to a new scaffold with the aim to develop novel FXR modulatory compounds.	Fatty Acids	52-62	nuclear receptor subfamily 1 group H member 4	Homo sapiens	143-146	
25869321-1	2015	LXR (encoded by NR1H2 and 3) and FXR (known as bile acid receptor) encoded by NR1H4 (nuclear receptor subfamily 1, group H and member 4) are nuclear receptors in humans and are important regulators of bile acid production, cholesterol, fatty acid and glucose homeostasis hence responsible for liver detoxification.	Fatty Acids	236-246	nuclear receptor subfamily 1 group H member 4	Homo sapiens	47-65	
20444884-4	2010	The FXR-SHP pathway is critical in maintaining bile acid and fatty acid homeostasis.	Fatty Acids	61-71	nuclear receptor subfamily 1 group H member 4	Homo sapiens	4-7	
20373033-8	2011	In view of the role of FAS and HL in lipogenesis and plasma lipoprotein metabolism, our results further support the central role of FXR in the homeostasis of fatty acid and lipid.	Fatty Acids	158-168	nuclear receptor subfamily 1 group H member 4	Homo sapiens	132-135	
15721319-7	2005	Thus, activation of FXR may suppress glycolysis and enhance oxidation of fatty acids via inactivation of the PDC by increasing PDK4 expression.	Fatty Acids	73-84	nuclear receptor subfamily 1 group H member 4	Homo sapiens	20-23	
33318189-7	2020	FXR deficiency increased the contribution of glutamine and fatty acids toward respiration and enhanced cell survival under low-glucose conditions.	Fatty Acids	59-70	nuclear receptor subfamily 1 group H member 4	Homo sapiens	0-3	
35066087-3	2022	Furthermore, many of the current NASH drug candidates specifically target pathways known to be under circadian control including fatty acid synthesis and signalling via farnesoid X receptor (FXR), fibroblast growth factor (FGF) 19 and 21, peroxisome proliferator-activated receptor (PPAR) alpha and gamma, glucagon like peptide 1 (GLP-1), and thyroid hormone receptor.	Fatty Acids	129-139	nuclear receptor subfamily 1 group H member 4	Homo sapiens	169-189	
35066087-3	2022	Furthermore, many of the current NASH drug candidates specifically target pathways known to be under circadian control including fatty acid synthesis and signalling via farnesoid X receptor (FXR), fibroblast growth factor (FGF) 19 and 21, peroxisome proliferator-activated receptor (PPAR) alpha and gamma, glucagon like peptide 1 (GLP-1), and thyroid hormone receptor.	Fatty Acids	129-139	nuclear receptor subfamily 1 group H member 4	Homo sapiens	191-194	
34615727-4	2022	This includes BA and fatty acid activated NRs such as farnesoid-X receptor (FXR) and peroxisome proliferator-activated receptors, respectively, for which high affinity therapeutic ligands targeting specific or multiple isoforms have been developed.	Fatty Acids	21-31	nuclear receptor subfamily 1 group H member 4	Homo sapiens	54-74	
34615727-4	2022	This includes BA and fatty acid activated NRs such as farnesoid-X receptor (FXR) and peroxisome proliferator-activated receptors, respectively, for which high affinity therapeutic ligands targeting specific or multiple isoforms have been developed.	Fatty Acids	21-31	nuclear receptor subfamily 1 group H member 4	Homo sapiens	76-79